CY1120796T1 - Συνδυασμος φαινοξυβενζαμινης και πολυμυξινης ε για την θεραπευτικη αντιμετωπιση των μικροβιακων λοιμωξεων - Google Patents
Συνδυασμος φαινοξυβενζαμινης και πολυμυξινης ε για την θεραπευτικη αντιμετωπιση των μικροβιακων λοιμωξεωνInfo
- Publication number
- CY1120796T1 CY1120796T1 CY181100667T CY181100667T CY1120796T1 CY 1120796 T1 CY1120796 T1 CY 1120796T1 CY 181100667 T CY181100667 T CY 181100667T CY 181100667 T CY181100667 T CY 181100667T CY 1120796 T1 CY1120796 T1 CY 1120796T1
- Authority
- CY
- Cyprus
- Prior art keywords
- agent
- treatment
- antifungal agent
- phenoxyvenzamine
- polymyxine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/305—Mercury compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται στη χρήση μίας ή περισσοτέρων ενώσεων που επιλέγονται από τις ακόλουθες κατηγορίες βιολογικά δραστικών παραγόντων: έναν α-αδρενεργικό ανταγωνιστή, έναν ανθελμινθικό παράγοντα, έναν αντιμυκητιασικό παράγοντα, έναν ανθελονοσιακό παράγοντα, έναν αντινεοπλασματικό παράγοντα, έναν αντιψυχωτικό παράγοντα, ένα αντιοξειδωτικό, ένα αγγειοδιασταλτικό και/ή μια βιταμίνη ή ένα φαρμακευτικά αποδεκτό παράγωγο αυτών για χρήση στη θεραπεία μιας μικροβιακής λοίμωξης και ειδικότερα για τη θανάτωση πολλαπλασιαστικών, μη πολλαπλασιαστικών και/ή κλινικά λανθανόντων μικροοργανισμών που σχετίζονται με μια τέτοια λοίμωξη.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1015079.5A GB201015079D0 (en) | 2010-09-10 | 2010-09-10 | Novel use |
PCT/GB2011/051695 WO2012032360A2 (en) | 2010-09-10 | 2011-09-09 | Novel use |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1120796T1 true CY1120796T1 (el) | 2019-12-11 |
Family
ID=43064989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY181100667T CY1120796T1 (el) | 2010-09-10 | 2018-06-27 | Συνδυασμος φαινοξυβενζαμινης και πολυμυξινης ε για την θεραπευτικη αντιμετωπιση των μικροβιακων λοιμωξεων |
Country Status (16)
Country | Link |
---|---|
US (2) | US10265373B2 (el) |
EP (2) | EP2613774B1 (el) |
JP (3) | JP6081359B2 (el) |
CA (2) | CA3026924A1 (el) |
CY (1) | CY1120796T1 (el) |
DK (1) | DK2613774T3 (el) |
ES (1) | ES2668168T3 (el) |
GB (1) | GB201015079D0 (el) |
HR (1) | HRP20180972T1 (el) |
HU (1) | HUE038705T2 (el) |
LT (1) | LT2613774T (el) |
PL (1) | PL2613774T3 (el) |
PT (1) | PT2613774T (el) |
RS (1) | RS57472B1 (el) |
SI (1) | SI2613774T1 (el) |
WO (1) | WO2012032360A2 (el) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201107755D0 (en) * | 2011-05-10 | 2011-06-22 | Helperby Therapeutics Ltd | Novel compounds |
US20150238473A1 (en) | 2012-09-27 | 2015-08-27 | University Of Rochester | Methods and compositions for treating infection |
US20150250808A1 (en) | 2012-10-15 | 2015-09-10 | Vojo P. Deretic | Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits |
US9861619B2 (en) | 2012-11-01 | 2018-01-09 | The University Of Chicago | Antibiotic methods and compositions for bacteria infections |
AU2014274830B2 (en) * | 2013-06-07 | 2017-11-09 | The California Institute For Biomedical Research | Small molecule inhibitors of fibrosis |
WO2015017328A2 (en) | 2013-07-29 | 2015-02-05 | Spallitta Frank Anthony | Organophosphates for treating afflictions of the skin |
US11446241B2 (en) | 2013-07-29 | 2022-09-20 | Attillaps Holdings Inc. | Treatment of ophthalmological conditions with acetylcholinesterase inhibitors |
CN103555590B (zh) * | 2013-09-27 | 2015-05-27 | 浙江工业大学 | 白地霉及其在制备(2r,3s)-苯基环氧丙酸乙酯中的应用 |
KR20150050406A (ko) * | 2013-10-29 | 2015-05-08 | 한림대학교 산학협력단 | 니코틴아마이드 라이보사이드를 유효성분으로 포함하는 패혈증 치료 또는 예방용 약제학적 조성물 |
CN103690522B (zh) * | 2013-12-08 | 2015-05-06 | 武汉威立得生物医药有限公司 | 一种草酸萘呋胺在制备治疗或预防流感病毒药物中的应用 |
RU2759673C2 (ru) | 2014-05-19 | 2021-11-16 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Наночастицы клевидипина и их фармацевтические композиции |
HRP20220854T1 (hr) | 2014-06-19 | 2022-10-14 | Attillaps Holdings | Inhibitori acetilkolinesteraze za liječenje dermatoloških stanja |
JP2017529393A (ja) | 2014-09-12 | 2017-10-05 | アンティバイオティクス エーピーエスAntibiotx Aps | ハロゲン化サリチルアニリドの抗菌用途 |
US10213478B2 (en) * | 2014-11-24 | 2019-02-26 | The Translational Genomics Research Institute | Compositions and methods for the treatment of fungal infections |
EP3233105B1 (en) * | 2014-12-18 | 2020-09-30 | Helperby Therapeutics Limited | Novel combination and use |
US9801909B2 (en) | 2015-04-06 | 2017-10-31 | The Penn State Research Foundation | Compositions and methods for combating bacterial infections by killing persister cells with mitomycin C |
GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
BR112018004069A2 (pt) | 2015-09-01 | 2021-07-13 | First Wave Bio, Inc. | composição farmacêutica sólida, preparação de enema compreendendo niclosamida, formulação de enema, uso de niclosamida e kit |
GB201616014D0 (en) | 2016-09-20 | 2016-11-02 | Helperby Therapeutics Ltd | Combination |
GB201616909D0 (en) * | 2016-10-05 | 2016-11-16 | Helperby Therapeutics Ltd | Combination |
GB201703898D0 (en) | 2017-03-10 | 2017-04-26 | Helperby Therapeautics Ltd | Method |
CA3057284A1 (en) * | 2017-03-21 | 2018-09-27 | Novalead Pharma Inc. | Therapeutic agent for phosphodiesterase inhibition and its related disorders |
GB201704620D0 (en) | 2017-03-23 | 2017-05-10 | Helperby Therapeautics Ltd | Combinations |
GB201709193D0 (en) | 2017-06-09 | 2017-07-26 | Helperby Therapeutics Ltd | Combination |
US10933061B2 (en) | 2017-12-21 | 2021-03-02 | Shepherd Therapeutics, Inc. | Pyrvinium pamoate therapies and methods of use |
CN108159039A (zh) * | 2018-02-28 | 2018-06-15 | 程伟 | 一种可用于制备抗结核病药物的化合物 |
EA202090767A1 (ru) * | 2018-05-04 | 2020-08-03 | Борис Славинович ФАРБЕР | Фармацевтическая композиция на основе полимиксина для лечения инфекционных заболеваний |
CN109431983A (zh) * | 2018-11-30 | 2019-03-08 | 合肥中龙神力动物药业有限公司 | 一种兽用复方伊维菌素注射液及其制备方法 |
CN109674754B (zh) * | 2019-01-10 | 2021-10-08 | 广东赛烽医药科技有限公司 | 一种氟哌噻吨美利曲辛药物组合物及其制剂 |
US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
JPWO2020179902A1 (el) * | 2019-03-06 | 2020-09-10 | ||
CN110237078B (zh) * | 2019-05-24 | 2022-02-18 | 深圳大学 | 醋酸巴多昔芬在抗结核分枝杆菌药物中的应用 |
CN110934870A (zh) * | 2019-12-20 | 2020-03-31 | 陕西科技大学 | 血根碱在抑制多重耐药雷氏普罗威登斯菌生长中的应用 |
US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
WO2021199056A1 (en) * | 2020-04-03 | 2021-10-07 | Kanishk Sinha | Vaccine for novel corona virus |
CN111419847A (zh) * | 2020-04-21 | 2020-07-17 | 济宁市第一人民医院 | 一种抑制屎肠球菌生长中的药物 |
CN111991404B (zh) * | 2020-10-10 | 2021-08-13 | 西南医科大学 | 防治真菌感染的复合维生素d及其应用 |
KR102315103B1 (ko) * | 2021-01-21 | 2021-10-20 | 주식회사 뉴캔서큐어바이오 | 티오리다진 및 퍼헥실린을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
KR102390542B1 (ko) * | 2021-10-05 | 2022-04-26 | 대한민국 | 클로미펜 시트레이트를 유효성분으로 포함하는 비결핵 항산균 감염 질환의 예방, 개선 또는 치료용 조성물 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1390748A (en) * | 1973-04-09 | 1975-04-16 | Continental Pharma | Alkyl and cycloalkylthiophenylalkylaminoalkanols their salts and the preparation thereof |
US5290774A (en) | 1989-08-03 | 1994-03-01 | Eisai Co., Ltd. | Photostabilizing method for ophthalmic solutions and the resulting ophthalmic solutions therefrom |
ES2034888B1 (es) | 1991-07-11 | 1994-02-16 | Madaus Cerafarm Lab | Procedimiento de obtencion de la fraccion acida total de los extractos lipidicos de los frutos del sabal serrulata. |
DE69427589T2 (de) | 1993-10-22 | 2002-04-25 | Smithkline Beecham Corp | Neue zusammensetzung |
US5698549A (en) * | 1994-05-12 | 1997-12-16 | Uva Patent Foundation | Method of treating hyperactive voiding with calcium channel blockers |
JP4489289B2 (ja) * | 1998-02-27 | 2010-06-23 | シンクロニュ−ロン,エルエルシ− | 肛門部の痛みのある状態を治療するための方法及びそのための組成物 |
WO2000028074A1 (en) | 1998-11-09 | 2000-05-18 | St. George's Enterprises Limited | Screening process for antibacterial agents |
TR200101991A2 (tr) | 2001-07-10 | 2003-02-21 | Özgenç Ki̇mya Gida San. Ve Ti̇c. Ltd. Şti̇. | Salamura kekik |
US6974585B2 (en) | 2001-08-01 | 2005-12-13 | Medlogic Global Limited | Durable multi-component antibiotic formulation for topical use |
AU2003222197A1 (en) | 2002-01-16 | 2003-09-02 | The Regents Of The University Of California | Inhibition of rna function |
CN1230160C (zh) | 2003-05-25 | 2005-12-07 | 杭州浙大力夫生物科技有限公司 | 竹叶总黄酮在制备前列腺疾病防治药物中的应用 |
US7410974B2 (en) | 2003-08-08 | 2008-08-12 | Ulysses Pharmaceutical Products, Inc. | Halogenated Quinazolinyl nitrofurans as antibacterial agents |
AU2005207037A1 (en) | 2004-01-22 | 2005-08-04 | Nitromed, Inc. | Nitrosated and/or nitrosylated compounds, compositions and methods of use |
CA2581775A1 (en) | 2004-09-27 | 2006-04-06 | Sigmoid Biotechnologies Limited | Dihydropyrimidine microcapsule - formulations |
KR20070091613A (ko) | 2004-11-08 | 2007-09-11 | 그렌마크 파머수티칼스 엘티디. | 항여드름 화합물 및 항생제 화합물을 함유하는 국소적 제약조성물 |
US7943600B2 (en) * | 2004-12-20 | 2011-05-17 | Massachusetts Institute Of Technology | Antimicrobial combination therapy |
WO2006086544A2 (en) | 2005-02-11 | 2006-08-17 | Regeneron Pharmaceuticals, Inc. | Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent |
US20060211645A1 (en) | 2005-03-04 | 2006-09-21 | Alsgen, Llc | Modulation of neurodegenerative diseases |
GB0505909D0 (en) * | 2005-03-23 | 2005-04-27 | Univ Leeds | Formulations |
GB0522715D0 (en) | 2005-11-08 | 2005-12-14 | Helperby Therapeutics Ltd | New use |
US20070154516A1 (en) | 2006-01-05 | 2007-07-05 | Drugtech Corporation | Drug delivery system |
US7910135B2 (en) | 2006-10-13 | 2011-03-22 | Uluru Inc. | Hydrogel wound dressing and biomaterials formed in situ and their uses |
GB0705915D0 (en) | 2007-03-28 | 2007-05-09 | Helperby Therapeutics Ltd | New use |
EP2182950B8 (en) | 2007-05-17 | 2017-08-23 | Helperby Therapeutics Limited | Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms |
WO2010026602A2 (en) | 2008-09-05 | 2010-03-11 | International Centre For Genetic Engineering And Biotechnology | Pharmaceutical compositions containing calcium channel blockers for treatment of tuberculosis |
-
2010
- 2010-09-10 GB GBGB1015079.5A patent/GB201015079D0/en not_active Ceased
-
2011
- 2011-09-09 SI SI201131510T patent/SI2613774T1/sl unknown
- 2011-09-09 CA CA3026924A patent/CA3026924A1/en not_active Abandoned
- 2011-09-09 LT LTEP11758257.7T patent/LT2613774T/lt unknown
- 2011-09-09 PT PT117582577T patent/PT2613774T/pt unknown
- 2011-09-09 PL PL11758257T patent/PL2613774T3/pl unknown
- 2011-09-09 HU HUE11758257A patent/HUE038705T2/hu unknown
- 2011-09-09 CA CA2809203A patent/CA2809203C/en not_active Expired - Fee Related
- 2011-09-09 DK DK11758257.7T patent/DK2613774T3/en active
- 2011-09-09 EP EP11758257.7A patent/EP2613774B1/en active Active
- 2011-09-09 JP JP2013527683A patent/JP6081359B2/ja not_active Expired - Fee Related
- 2011-09-09 ES ES11758257.7T patent/ES2668168T3/es active Active
- 2011-09-09 EP EP17166322.2A patent/EP3228314B1/en active Active
- 2011-09-09 RS RS20180752A patent/RS57472B1/sr unknown
- 2011-09-09 WO PCT/GB2011/051695 patent/WO2012032360A2/en active Application Filing
- 2011-09-09 US US13/821,448 patent/US10265373B2/en not_active Expired - Fee Related
-
2015
- 2015-09-22 US US14/862,108 patent/US9549965B2/en active Active
-
2017
- 2017-01-18 JP JP2017006530A patent/JP2017066165A/ja active Pending
-
2018
- 2018-06-26 HR HRP20180972TT patent/HRP20180972T1/hr unknown
- 2018-06-27 CY CY181100667T patent/CY1120796T1/el unknown
-
2019
- 2019-08-01 JP JP2019142291A patent/JP2019182877A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20130243886A1 (en) | 2013-09-19 |
EP3228314B1 (en) | 2020-11-04 |
JP2013537184A (ja) | 2013-09-30 |
HRP20180972T1 (hr) | 2018-10-05 |
EP2613774A2 (en) | 2013-07-17 |
WO2012032360A3 (en) | 2012-05-10 |
WO2012032360A2 (en) | 2012-03-15 |
US20160082073A1 (en) | 2016-03-24 |
JP6081359B2 (ja) | 2017-02-15 |
RS57472B1 (sr) | 2018-09-28 |
ES2668168T3 (es) | 2018-05-17 |
HUE038705T2 (hu) | 2018-11-28 |
DK2613774T3 (en) | 2018-07-16 |
PL2613774T3 (pl) | 2018-10-31 |
CA3026924A1 (en) | 2012-03-15 |
CA2809203A1 (en) | 2012-03-15 |
SI2613774T1 (sl) | 2018-09-28 |
PT2613774T (pt) | 2018-05-22 |
US9549965B2 (en) | 2017-01-24 |
LT2613774T (lt) | 2018-09-10 |
CA2809203C (en) | 2019-01-29 |
EP3228314A1 (en) | 2017-10-11 |
JP2017066165A (ja) | 2017-04-06 |
GB201015079D0 (en) | 2010-10-27 |
EP2613774B1 (en) | 2018-03-28 |
JP2019182877A (ja) | 2019-10-24 |
US10265373B2 (en) | 2019-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120796T1 (el) | Συνδυασμος φαινοξυβενζαμινης και πολυμυξινης ε για την θεραπευτικη αντιμετωπιση των μικροβιακων λοιμωξεων | |
CY1122761T1 (el) | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων | |
PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
CY1119361T1 (el) | 3,4-διυδροισοκινολιν-2(1h)-υλικες ενωσεις | |
CY1112860T1 (el) | 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες | |
CY1117067T1 (el) | Η χρηση σωματιδιων στερεων φορεων για τη βελτιωση της επεξεργασιμοτητας φαρμακευτικου παραγοντα | |
CY1124331T1 (el) | Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης | |
BR112015022391A8 (pt) | inibidores de domínio bromo tetracíclico | |
BR112015022551A2 (pt) | inibidores de amido pirrol | |
ECSP12012326A (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
CL2009000426A1 (es) | Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas | |
MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
AU2011274192A8 (en) | Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof | |
BR112012023382A2 (pt) | compostos, composições e métodos de uso de imidazopiridina. | |
UY32158A (es) | Derivados heterociclicos y metodos de uso de los mismos | |
BR112012024796A2 (pt) | inibidores de integrase macrocíclicos | |
EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
EA201300617A1 (ru) | β-ЛАКТАМОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ β-ЛАКТАМАЗЫ И ИХ ПРИМЕНЕНИЕ | |
SV2010003752A (es) | Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas | |
UY31865A (es) | Derivados de urea heterocíclicos y métodos para la utilización de los mismos | |
EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
EA201591175A1 (ru) | Трициклические соединения в качестве ингибиторов cftr | |
BR112015010570B8 (pt) | agentes microbianos, composto e seu uso e composição farmacêutica | |
MX2019004484A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. | |
EA201290229A1 (ru) | Производные спиролактама и их применение |